Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;49:962-970
Published online before print March 26, 2007, doi: 10.1161/HYPERTENSIONAHA.106.079426
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
49/5/962    most recent
HYPERTENSIONAHA.106.079426v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dorn, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorn, G. W., II
Related Collections
Right arrow Structure
Right arrow Biochemistry and metabolism
Right arrow Congestive

(Hypertension. 2007;49:962.)
© 2007 American Heart Association, Inc.


Brief Reviews

The Fuzzy Logic of Physiological Cardiac Hypertrophy

Gerald W. Dorn, II

From the Center for Molecular Cardiovascular Research, University of Cincinnati, Ohio.

Correspondence to Gerald W. Dorn II, Molecular Cardiovascular Research, University of Cincinnati, 231 Albert Sabin Way, ML 0839, Cincinnati, OH 45267-0839. E-mail dorngw@ucmail.uc.edu


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
Cardiac hypertrophy is defined as an abnormal increase in heart muscle mass and is functionally, mechanistically, and histologically distinguished from normal embryonic and postnatal myocardial growth by characteristic changes in cardiac myocyte shape and volume.1 Reactive hypertrophy, that is, hypertrophy that occurs in response to an extrinsic increase in cardiac work,2 is distinguished from genetic familial hypertrophic cardiomyopathy mutations3 in which the stimulus for hypertrophy is intrinsic to the cardiomyocyte. In the prototypical reactive hypertrophic response to pressure overload, decreased wall stress (estimated as the ratio of ventricular radius to wall thickness; Figure 1) resulting from "compensatory" cardiac hypertrophy provides mechanical advantages that help normalize ejection performance in the face of increased workload as originally described by Grossman et al4 (Figure 1). These mechanical benefits accrue whether the stimulus for hypertrophy is intermittent, as with exercise training that produces "physiological hypertrophy," or sustained, as with hypertension or aortic stenosis that produce "pathological hypertrophy." With sustained hemodynamic overload, however, progressive systolic dysfunction ultimately occurs that leads to heart failure (Figure 1). The realization that prolonged, continuous hemodynamic stress will ultimately lead to hypertrophy decompensation, together with accumulating information that the hypertrophied myocardium is transcriptionally and biochemically distinct from normal myocardium,5 lead Katz to derive the concept of a "cardiomyopathy of pressure overload,"6 which is a specific contextual application of the notion of pathological hypertrophy.


Figure Removed (Available Only in the Full Text)
View larger version (15K):



 
Figure 1. Stimulus-specific hypertrophic responses of the heart and how they affect wall stress (c), which, at equal pressures, is proportional to . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
L. Zelarayan, A. Renger, C. Noack, M.-P. Zafiriou, C. Gehrke, R. van der Nagel, R. Dietz, L. de Windt, and M. W. Bergmann
NF-{kappa}B activation is required for adaptive cardiac hypertrophy
Cardiovasc Res, December 1, 2009; 84(3): 416 - 424.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. M. McNicholas and K. H. Berecek
Mammalian Target of Rapamycin: MasTOR Mediator of Cellular Changes in Pathological States?
Hypertension, December 1, 2009; 54(6): 1221 - 1222.
[Full Text] [PDF]


Home page
Circ Heart FailHome page
D. Lachance, E. Plante, A.-A. Bouchard-Thomassin, S. Champetier, E. Roussel, M.-C. Drolet, M. Arsenault, and J. Couet
Moderate Exercise Training Improves Survival and Ventricular Remodeling in an Animal Model of Left Ventricular Volume Overload
Circ Heart Fail, September 1, 2009; 2(5): 437 - 445.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. D. Garciarena, O. A. Pinilla, M. B. Nolly, R. P. Laguens, E. M. Escudero, H. E. Cingolani, and I. L. Ennis
Endurance Training in the Spontaneously Hypertensive Rat: Conversion of Pathological into Physiological Cardiac Hypertrophy
Hypertension, April 1, 2009; 53(4): 708 - 714.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Cai, F.-F. Yi, L. Yang, D.-F. Shen, Q. Yang, A. Li, A. K. Ghosh, Z.-Y. Bian, L. Yan, Q.-Z. Tang, et al.
Targeted Expression of Receptor-Associated Late Transducer Inhibits Maladaptive Hypertrophy via Blocking Epidermal Growth Factor Receptor Signaling
Hypertension, March 1, 2009; 53(3): 539 - 548.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. W. Bergmann and L. Zelarayan
RALT Specifically Halts Maladaptive Cardiac Hypertrophy: A New Kid on the Block
Hypertension, March 1, 2009; 53(3): 454 - 455.
[Full Text] [PDF]


Home page
Circ. Res.Home page
B. A. Rothermel and J. A. Hill
Autophagy in Load-Induced Heart Disease
Circ. Res., December 5, 2008; 103(12): 1363 - 1369.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. Kim, A. R. Wende, S. Sena, H. A. Theobald, J. Soto, C. Sloan, B. E. Wayment, S. E. Litwin, M. Holzenberger, D. LeRoith, et al.
Insulin-Like Growth Factor I Receptor Signaling Is Required for Exercise-Induced Cardiac Hypertrophy
Mol. Endocrinol., November 1, 2008; 22(11): 2531 - 2543.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J.-L. Samuel, M. C. Schaub, M. Zaugg, M. Mamas, W. B. Dunn, and B. Swynghedauw
Genomics in cardiac metabolism
Cardiovasc Res, July 15, 2008; 79(2): 218 - 227.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. A. Hill and E. N. Olson
Cardiac Plasticity
N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380.
[Full Text] [PDF]


Home page
CirculationHome page
A. Diwan, J. Wansapura, F. M. Syed, S. J. Matkovich, J. N. Lorenz, and G. W. Dorn II
Nix-Mediated Apoptosis Links Myocardial Fibrosis, Cardiac Remodeling, and Hypertrophy Decompensation
Circulation, January 22, 2008; 117(3): 396 - 404.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
R. Q Osborn, W. C Taylor, K. Oken, M. Luzano, M. Heckman, and G. Fletcher
Echocardiographic characterisation of left ventricular geometry of professional male tennis players
Br. J. Sports Med., November 1, 2007; 41(11): 789 - 792.
[Abstract] [Full Text] [PDF]